FlexiCath

Company Overview

Snapshot

Founded in January 2004, FlexiCath operates with 11–50 employees. The company is currently in a Pre-Funding stage, focusing on developing its M/29 Midterm Catheter System.

Business overview

FlexiCath develops and commercializes sterile catheter insertion systems designed to address challenges in midterm IV catheterization, specifically for indwelling periods up to 29 days. The company's core product, the M/29 Midterm Catheter System, integrates proprietary innovations with established industry technology to provide a safe, touch-free midline catheter that can be inserted efficiently with minimal training. FlexiCath operates within the Health Tech & Life Sciences sector, with a focus on medical devices and medical treatment & therapeutics, serving the healthcare industry.

Company Intelligence Q&A

What is FlexiCath's primary product?

FlexiCath's primary product is the M/29 Midterm Catheter System, a sterile, touch-free midline catheter designed for intermediate dwell applications of up to 29 days.

What problem does FlexiCath aim to solve?

FlexiCath aims to solve issues associated with midterm IV catheterization by providing a safe and easy-to-insert sterile catheter system.

In which sector does FlexiCath primarily operate?

FlexiCath primarily operates in the Health Tech & Life Sciences sector, specifically focusing on medical devices and medical treatment & therapeutics.

When was FlexiCath founded?

FlexiCath was founded in January 2004.

What is the current status of FlexiCath?

FlexiCath's status is Non Active as of November 2016.